In vitro activity of probiotic Lactobacillus reuteri against gastric cancer progression by downregulation of urokinase plasminogen activator/urokinase plasminogen activator receptor gene expression

被引:32
|
作者
Rasouli, Bahareh Sadat [1 ,2 ]
Ghadimi-Darsajini, Ali [1 ,2 ]
Nekouian, Reza [1 ,2 ]
Iragian, Gholam-Reza [3 ]
机构
[1] Iran Univ Med Sci, Sch Allied Med, Dept Med Biotechnol, Tehran, Iran
[2] Iran Univ Med Sci, Cellular & Mol Res Ctr, Tehran, Iran
[3] Iran Univ Med Sci, Sch Med, Dept Microbiol, Tehran, Iran
关键词
Gastric cancer; Lactobacillus reuteri; urokinase plasminogen activator; urokinase plasminogen activator receptor; NF-KAPPA-B; HELICOBACTER-PYLORI; CELL-PROLIFERATION; AGS CELLS; SYSTEM; UPAR; INHIBITION; INVASION; MAPK;
D O I
10.4103/0973-1482.204897
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Gastric cancer (GC) is the third leading cause of cancer death, and most patients represent metastatic phenotype at the time of diagnosis. Urokinase plasminogen activator (uPA) system is well known for its critical roles in cancer cells invasion since uPA/uPA receptor (uPAR) overexpresses in several cancers. Subsequently, suppression of uPA/uPAR gene expression improves patients overall survival and prevents cancer progression. Objectives: The aim of the current study was to investigate possible effects of live Lactobacillus reuteri as a probiotic in inhibition of GC cells proliferation and invasion. Materials and Methods: Human gastric adenocarcinoma epithelial cell line (AGS) cells were treated with different ratios of live L. reuteri and were incubated for 24, 48, and 72 h. Viability of cancer cells was measured with 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide assay, and the effects of L. reuteri on uPA/uPAR gene expression were assessed by real-time polymerase chain reaction. Results: Our results showed that L. reuteri inhibits cell proliferation significantly in dose-dependent manner. Expressions of uPA and uPAR were downregulated followed by co-incubation of AGS cells and live L. reuteri compared to untreated-based line level. Conclusion: This study provides strong support in the role of L. reuteri in suppression of GC cell invasion by downregulation of pathways which is involved in extracellular matrix degradation such as uPA and uPAR.
引用
收藏
页码:246 / 251
页数:6
相关论文
共 50 条
  • [21] Role of Urokinase Plasminogen Activator Receptor in Gastric Cancer: A Potential Therapeutic Target
    Ma, Ying-Yu
    Tao, Hou-Quan
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2012, 27 (05) : 285 - 290
  • [22] Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role
    Mario Plebani
    Làszlo Herszènyi
    Paolo Carraro
    Massimo De Paoli
    Giovanni Roveroni
    Romilda Cardin
    Zsolt Tulassay
    Remo Naccarato
    Fabio Farinati
    Clinical & Experimental Metastasis, 1997, 15 : 418 - 426
  • [23] Urokinase type plasminogen activator receptor expression in colorectal neoplasms
    Suzuki, S
    Hayashi, Y
    Wang, Y
    Nakamura, T
    Morita, Y
    Kawasaki, K
    Ohta, K
    Aoyama, N
    Kim, SR
    Itoh, H
    Kuroda, Y
    Doe, WF
    GUT, 1998, 43 (06) : 798 - 805
  • [24] Soluble urokinase-type plasminogen activator receptor and urokinase-type plasminogen activator receptor contribute to chemoresistance in leukemia
    Guo, Hong
    Zhou, Lan-Xia
    Ma, Haizhen
    Liu, Bei
    Cheng, Juan
    Ma, Yun-Yun
    Zhao, Li
    ONCOLOGY LETTERS, 2017, 14 (01) : 383 - 389
  • [25] Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors
    Gutova, Margarita
    Najbauer, Joseph
    Frank, Richard T.
    Kendall, Stephen Edward
    Gevorgyan, Anna
    Metz, Marianne Z.
    Guevorkian, Mark
    Edmiston, Marissa
    Zhao, Donghong
    Glackin, Carlotta A.
    Kim, Seung U.
    Aboody, Karen S.
    STEM CELLS, 2008, 26 (06) : 1406 - 1413
  • [26] Urokinase plasminogen activator receptor: Prognostic biomarker for endometrial cancer
    Memarzedeh, S
    Kozak, KR
    Chang, L
    Natarajan, S
    Shintaku, P
    Reddy, ST
    Farias-Eisner, R
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (16) : 10647 - 10652
  • [27] Urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) serum level in patients with malignant lymphomas
    Hus, I
    Cioch, M
    Jawniak, D
    Manko, J
    Dmoszynska, A
    Chrapko, M
    Hus, M
    BULLETIN OF THE VETERINARY INSTITUTE IN PULAWY, 2002, : 141 - 144
  • [28] The urokinase-type plasminogen activator and its receptor in cancer
    Rosenberg, S
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 34, 1999, 34 : 121 - 128
  • [29] The role of urokinase type plasminogen activator receptor in colorectal cancer
    Herszenyi, L
    Farinati, F
    Plebani, M
    Carraro, P
    De Paoli, M
    Istvan, G
    Sapi, Z
    Naccarato, R
    Tulassay, Z
    GASTROENTEROLOGY, 1999, 116 (04) : A421 - A421
  • [30] Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer
    GrondahlHansen, J
    Peters, HA
    vanPutten, WLJ
    Look, MP
    Pappot, H
    Ronne, E
    Dano, K
    Klijn, JGM
    Brunner, N
    Foekens, JA
    CLINICAL CANCER RESEARCH, 1995, 1 (10) : 1079 - 1087